Company Overview of ScarX Therapeutics Inc.
ScarX Therapeutics Inc., a biotechnology company, discovers and develops treatments for dermal scarring (fibrosis). It develops SCX-001, a topical prescription cream to treat and prevent post-surgical scarring; and Nefopam active drug substance in SCX-001, a small molecule that inhibits the production of catenin, the protein associated with hypertrophic (excessive) scarring in animals and humans. The company serves customers worldwide. ScarX Therapeutics Inc. was founded in 2012 and is based in Toronto, Canada.
661 University Ave
Toronto, ON M5G 1M1
Founded in 2012
Key Executives for ScarX Therapeutics Inc.
ScarX Therapeutics Inc. Key Developments
Similar Private Companies By Industry
|2007262 Ontario, Inc.||Americas|
|2056273 Ontario, Inc.||Americas|
|AB BioPharma Inc.||Americas|
|AbCelex Technologies Inc.||Americas|
|AbCellera Biologics Inc.||Americas|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact ScarX Therapeutics Inc., please visit www.scarxtherapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.